Related Experiment Video
Updated: Jul 3, 2026

Measurement of Tissue Oxygenation Using Near-Infrared Spectroscopy in Patients Undergoing Hemodialysis
Published on: October 2, 2020
Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end
A Covic1, A Seica, P Gusbeth-Tatomir
1Nephrology Clinic, 'Dr. C. I. Parhon' University Hospital, Iasi - Romania. acovic@xnet.ro
Abstract:
This editorial review takes an in-depth look to the effect of hemoglobin (Hb) normalization with erythropoietin on quality of life (QoL) in chronic kidney disease (CKD). The analysis of the current available data shows major inhomogeneities in the tools used for assessment of QoL and in data reporting. Furthermore, the major trials on Hb normalization were generally not primarily designed to analyze QoL as a specific end-point. However, current data suggest that only partial correction of anemia with EPO may improve QoL, whereas correction of Hb to above 12 g/dL does not exert any positive effect. Finally, the authors provide recommendations on a more rigorous assessment of QoL in future trials in CKD patients.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Serum Studies: Renal Function Tests
Chronic Kidney Disease I: Introduction
Acute Kidney Injury III: Clinical Manifestations